Literature DB >> 17973265

Hereditary nonpolyposis colorectal cancer in endometrial cancer patients.

Sang Nam Yoon1, Ja-Lok Ku, Young-Kyoung Shin, Kyung-Hee Kim, Jin-Sung Choi, Eun-Ja Jang, Hyoung-Chul Park, Duck-Woo Kim, Min A Kim, Woo Ho Kim, Taek Sang Lee, Jae Weon Kim, Noh-Hyun Park, Yong-Sang Song, Soon-Beom Kang, Hyo-Pyo Lee, Seung-Yong Jeong, Jae-Gahb Park.   

Abstract

Endometrial cancer is the second most common cancer in hereditary nonpolyposis colorectal cancer (HNPCC). It has often been overlooked to explore the possibility of HNPCC in endometrial cancer patients. Our study was to investigate how many HNPCC patients existed among endometrial cancer patients. Among patients who underwent hysterectomy for endometrial cancer at Seoul National University Hospital from 1996 to 2004, 113 patients were included, whose family history and clinical data could be obtained and tumor specimens were available for microsatellite instability (MSI) testing and immunohistochemical (IHC) staining of MLH1, MSH2 and MSH6 proteins. There were 4 (3.5%) clinical HNPCC patients fulfilling the Amsterdam criteria II, and 2 (2/4, 50%) of them carried MSH2 germline mutations. There were also 8 (7.1%) suspected HNPCC (s-HNPCC) patients fulfilling the revised criteria for s-HNPCC, and one (1/8, 12.5%) of them revealed MLH1 germline mutation. In 101 patients, who were not clinical HNPCC or s-HNPCC, 11 patients showed both MSI-high and loss of expression of MLH1, MSH2 or MSH6 proteins, and 2 (2/11, 18.2%) of them showed MSH6 germline mutations. In 113 patients with endometrial cancer, we could find 5 (4.4%) HNPCC patients with MMR germline mutation and 2 (1.8%) clinical HNPCC patients without identified MMR gene mutation. Family history was critical in detecting 3 HNPCC patients with MMR germline mutation, and MSI testing with IHC staining for MLH1, MSH2 and MSH6 proteins was needed in the diagnosis of 2 HNPCC patients who were not clinical HNPCC or s-HNPCC, especially for MSH6 germline mutation. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17973265     DOI: 10.1002/ijc.22986

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  14 in total

1.  Clinicopathologic characteristics of colorectal cancer patients with synchronous and metachronous gastric cancer.

Authors:  Sang Nam Yoon; Sung Tae Oh; Seok-Byung Lim; Tae Won Kim; Jong Hoon Kim; Chang Sik Yu; Jin Cheon Kim
Journal:  World J Surg       Date:  2010-09       Impact factor: 3.352

Review 2.  Endometrial tumour BRAF mutations and MLH1 promoter methylation as predictors of germline mismatch repair gene mutation status: a literature review.

Authors:  Alexander M Metcalf; Amanda B Spurdle
Journal:  Fam Cancer       Date:  2014-03       Impact factor: 2.375

3.  Case-case study of factors associated to hMLH1, hMSH2, and hMSH6 protein expression among endometrial cancer patients of the University District Hospital of San Juan, Puerto Rico.

Authors:  Lorena González; Ana P Ortiz; Erick L Suárez; Sharee Umpierre; Jorge Billoch; Maria J Marcos; Leilani Joy; Eileen Charneco; Mercedes Y Lacourt; Raúl D Bernabe-Dones; Marcia R Cruz-Correa
Journal:  Int J Gynecol Cancer       Date:  2012-06       Impact factor: 3.437

4.  Effects of tamoxifen on the endometrium and its mechanism of carcinogenicity.

Authors:  Akira Yasue; Kiyoshi Hasegawa; Yasuhiro Udagawa
Journal:  Hum Cell       Date:  2011-01-22       Impact factor: 4.174

5.  Mismatch repair protein expression and colorectal cancer in Hispanics from Puerto Rico.

Authors:  Wilfredo E De Jesus-Monge; Carmen Gonzalez-Keelan; Ronghua Zhao; Stanley R Hamilton; Miguel Rodriguez-Bigas; Marcia Cruz-Correa
Journal:  Fam Cancer       Date:  2010-06       Impact factor: 2.375

6.  CoDP: predicting the impact of unclassified genetic variants in MSH6 by the combination of different properties of the protein.

Authors:  Hiroko Terui; Kiwamu Akagi; Hiroshi Kawame; Kei Yura
Journal:  J Biomed Sci       Date:  2013-04-28       Impact factor: 8.410

7.  Synchronous gynecologic malignancy and preliminary results of Lynch syndrome.

Authors:  Min Kyu Kim; Sang Yong Song; In-Gu Do; Seo-Hee Kim; Chel Hun Choi; Tae-Joong Kim; Jeong-Won Lee; Duk-Soo Bae; Byoung-Gie Kim
Journal:  J Gynecol Oncol       Date:  2011-12-05       Impact factor: 4.401

8.  Testing strategies for Lynch syndrome in people with endometrial cancer: systematic reviews and economic evaluation.

Authors:  Chris Stinton; Mary Jordan; Hannah Fraser; Peter Auguste; Rachel Court; Lena Al-Khudairy; Jason Madan; Dimitris Grammatopoulos; Sian Taylor-Phillips
Journal:  Health Technol Assess       Date:  2021-06       Impact factor: 4.014

9.  Missense mutations of MLH1 and MSH2 genes detected in patients with gastrointestinal cancer are associated with exonic splicing enhancers and silencers.

Authors:  Ming Zhu; Hui-Mei Chen; Ya-Ping Wang
Journal:  Oncol Lett       Date:  2013-03-11       Impact factor: 2.967

10.  The role of positive selection in determining the molecular cause of species differences in disease.

Authors:  Jessica J Vamathevan; Samiul Hasan; Richard D Emes; Heather Amrine-Madsen; Dilip Rajagopalan; Simon D Topp; Vinod Kumar; Michael Word; Mark D Simmons; Steven M Foord; Philippe Sanseau; Ziheng Yang; Joanna D Holbrook
Journal:  BMC Evol Biol       Date:  2008-10-06       Impact factor: 3.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.